- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06051942
PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs
March 1, 2024 updated by: PROCEPT BioRobotics
The goal of this clinical trial is to assess the performance and safety of the AQUABEAM Robotic System for the resection and removal of prostate tissue in patients experiencing lower urinary tract symptoms (LUTS) and are diagnosed with localized prostate cancer.
Participants will go through baseline and follow up assessments up to 12 months.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
125
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Angela Lee
- Phone Number: 650-232-7215
- Email: a.lee@procept-biorobotics.com
Study Locations
-
-
-
Hong Kong, Hong Kong
- Recruiting
- The Chinese University of Hong Kong
-
Contact:
- Becky Lau
- Phone Number: +852 35 053933
- Email: beckylau@surgery.cuhk.edu.hk
-
-
-
-
-
Beirut, Lebanon
- Recruiting
- American University of Beirut
-
Contact:
- Aline Yacoubian
- Phone Number: + 961 3 705 235
- Email: ay12@aub.edu.lb
-
-
-
-
Illinois
-
Glenview, Illinois, United States, 60026
- Recruiting
- NorthShore University HealthSystem
-
Contact:
- Pooja Talaty, MS MHA CCRP
- Phone Number: 847-503-4280
- Email: PTalaty@northshore.org
-
-
Texas
-
Austin, Texas, United States, 78745
- Not yet recruiting
- Urology Austin, PLLC
-
Contact:
- Jennifer Penshorn, RN
- Phone Number: 512-410-3773
- Email: jennifer.penshorn@urologyaustin.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- International Prostate Symptom Score (IPSS) ≥ 8
- Gleason Grade Group 1-3
- Prostate-specific Antigen (PSA) ≤20ng/mL
- Cancer stage less than or equal to T2c
Exclusion Criteria:
- Patients with previous surgical treatment of benign prostatic hyperplasia
- MRI evidence of extracapsular extension of cancer
- Any severe illness that would prevent complete study participation or confound study results
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Aquablation
|
The Aquablation therapy is a minimally invasive, image-guided, heat-free robotic therapy delivered by the AQUABEAM Robotic System.
During Aquablation therapy, the AQUABEAM Handpiece is inserted transurethrally into the prostatic urethra.
The operating physician then utilizes cystoscopy in conjunction with transrectal ultrasound (TRUS) imaging for real time visualization.
The AQUABEAM Robotic System utilizes high-velocity sterile saline waterjet to resect and remove the prostate tissue according to the operating physician's treatment plan.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Clavien-Dindo Adverse Events (Percentage of Participants) Through 3 Months Post Treatment
Time Frame: 3 months post-treatment
|
Proportion (percentage) of participants with adverse events rated as related to the study procedure classified as Clavien-Dindo Grade 2 or higher or any Grade 1 event resulting in persistent disability (ejaculatory disorder, erectile dysfunction, or incontinence) evidenced through 3 months post-treatment.
|
3 months post-treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 22, 2022
Primary Completion (Estimated)
August 1, 2025
Study Completion (Estimated)
May 1, 2026
Study Registration Dates
First Submitted
September 18, 2023
First Submitted That Met QC Criteria
September 18, 2023
First Posted (Actual)
September 25, 2023
Study Record Updates
Last Update Posted (Estimated)
March 5, 2024
Last Update Submitted That Met QC Criteria
March 1, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CSP0003
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Benign Prostatic Hyperplasia
-
St. Joseph's Healthcare HamiltonOntario Ministry of Health and Long Term CareCompletedBenign Prostatic HyperplasiaCanada
-
San Carlo di Nancy HospitalElesta S.R.L.CompletedBenign Prostatic Hyperplasia | Benign Prostatic Hypertrophy | Benign Prostatic Hypertrophy With Outflow Obstruction | Prostate HyperplasiaItaly
-
GlaxoSmithKlineCompletedBenign Prostatic Hyperplasia
-
Catholic University of the Sacred HeartCompletedBenign Prostatic Hyperplasia (BPH) | Benign Prostatic Enlargement (BPE)Italy
-
Boston Scientific CorporationCompletedProstatic Hyperplasia | Benign Prostatic Hyperplasia | Prostatic Hyperplasia, Benign | Prostatic Hypertrophy | Prostatic Hypertrophy, Benign | Adenoma, Prostatic | Prostatic Adenoma | RezumDominican Republic, Czechia, Sweden
-
Boston Scientific CorporationCompletedBenign Prostatic Hyperplasia | Prostatic Hyperplasia, Benign | Prostatic Hypertrophy | Prostatic Hypertrophy, Benign | Adenoma, Prostatic | Prostatic Adenoma | RezumDominican Republic
-
IMBiotechnologies Ltd.CompletedBenign Prostatic Hyperplasia | Benign Prostatic HypertrophyCanada
-
IRCCS Policlinico S. MatteoCompletedBenign Prostatic Hyperplasia | Benign Prostatic Hypertrophy With Outflow ObstructionItaly
-
American Medical SystemsCompletedBenign Prostatic Hyperplasia | BPH | Benign Prostatic Hypertrophy | Prostate Disease
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Not yet recruitingLower Urinary Tract Symptoms | Benign Prostate Hyperplasia | Benign Prostatic Hypertrophy With Outflow Obstruction
Clinical Trials on Robotic Waterjet Treatment
-
PROCEPT BioRoboticsRecruitingLocalized Prostate CancerUnited States
-
Auxilium Vitae VolterraAzienda USL Toscana Nord Ovest; Scuola Superiore Sant'Anna di PisaCompletedStroke | Muscle Spasticity
-
Evangelisches Krankenhaus DüsseldorfCompletedBarrett Adenocarcinoma | High Grade Intraepithelial NeoplasiaGermany
-
IRCCS Centro Neurolesi "Bonino-Pulejo"Completed
-
IRCCS Centro Neurolesi "Bonino-Pulejo"Unknown
-
Riyadh Colleges of Dentistry and PharmacyUnknown
-
National Taiwan University HospitalUnknown
-
Karolinska University HospitalBengt Isaksson; Jansson, Anders, M.D.Completed
-
Milton S. Hershey Medical CenterCompleted
-
National Taiwan University HospitalUnknown